Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Docosanol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aleor Dermaceuticals Receives Final USFDA Approval for Cold Sore Drug
Details : Docosanol is a drug used for topical treatment for recurrent herpes simplex labialis episodes, inhibits fusion between plasma membrane and herpes simplex virus envelope, thereby preventing viral entry into cells and subsequent viral replication.
Product Name : Docosanol-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2022
Lead Product(s) : Docosanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mupirocin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Alembic Pharmaceuticals Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mupirocin cream USP, 2% is indicated for the treatment of secondarily infected traumatic skin lesions due to susceptible strains of S. aureus and S. pyogenes.
Product Name : Mupirocin
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 17, 2021
Lead Product(s) : Mupirocin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Alembic Pharmaceuticals Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efinaconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Efinaconazole Topical Solution, 10% is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2021
Lead Product(s) : Efinaconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metronidazole
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aleor Dermaceuticals Receives US FDA Approval for Metrogel Gel
Details : Aleor Dermaceuticals has received final approval from the US FDA for its Abbreviated New Drug Application for metronidazole gel USP, 1%. The ANDA is therapeutically equivalent to the reference listed drug product (RLD), Metrogel gel, 1%, of Galderma Labo...
Product Name : Metrogel
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 09, 2021
Lead Product(s) : Metronidazole
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nystatin,Triamcinolone Acetonide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/gram, of Taro Pharmaceuticals U.S.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 04, 2021
Lead Product(s) : Nystatin,Triamcinolone Acetonide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Testosterone gel, 1.62% (20.25 mg/1.25 gm actuation) is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism and Hypogonadotropic hypogonadism.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 25, 2020
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tavaborole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aleor Dermaceuticals Receives USFA Tentative Approval for Antifungal Medication
Details : Aleor Dermaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tavaborole Topical Solution, 5%.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 13, 2020
Lead Product(s) : Tavaborole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable